Medwave Inc. and Nihon Kohden Expand Agreements

Apr 19, 2001, 01:00 ET from Medwave Inc.

    ST. PAUL, Minn., April 19 /PRNewswire/ -- Medwave, Inc. (Nasdaq: MDWV)
 announced today that Nihon Kohden, Tokyo Japan, will assist Medwave in
 submitting the Vasotrax(TM) Hand-held Blood Pressure Monitor to Japans
 Ministry of Health and Welfare.  Later in the year, the companies will review
 the possibility of Nihon Kohden representing Medwaves Vasotrax Hand-held Blood
 Pressure Monitor in the Japanese Market.
     Medwave just recently introduced the Vasotrax Hand-held Blood Pressure
 Monitor.  With Vasotrax, clinicians can obtain spot blood pressure readings in
 approximately 15 seconds.  The Vasotrax eliminates the need for a conventional
 blood pressure cuff, uses no mercury, and has been compared to an arterial
 catheter, with an accuracy of 0.90.  Conventional non-invasive blood pressure
 products typically have an accuracy correlation of 0.70-0.80, versus an
 A-line.  In the future users will be able to store over 200 readings, which
 can be download into a PC Based System, for up to 16 patients.
     Medwave and Nihon Kohden have two other existing agreements.  In Japan,
 Nihon Kohden is the exclusive distribution company for the Vasotrac(R) APM205A
 Continual Non-invasive Blood Pressure Monitor, which was submitted to Japans
 Ministry of Health and Welfare several months ago.  Also, in an agreement
 finalized in September 2000, Medwave supplies Nihon Kohden with an OEM module
 of the Vasotrac for the Nihon Kohden Product Family.
     The Vasotrac is designed for measuring a patient's blood pressure on a
 continual basis.  It provides updates approximately once every 15 heartbeats,
 with an accuracy correlation of 0.97 versus an arterial catheter.  The
 Vasotrac is being marketed in several major countries in the world including
 the United States and Europe.  The Vasotrac is currently being used in
 anesthesiology, critical care, emergency rooms, and cardiology departments.
 Users of the Vasotrac have reported a reduction in the need for arterial
 catheters, when used with specific patients.
     Medwave, Inc. headquartered in St. Paul, Minn., USA, develops and
 manufactures non-invasive blood pressure products.  Its Vasotrax Hand-held
 Monitor and the Vasotrac(R) APM205A monitor, the company's related monitoring
 system, are new approaches to non-invasive blood pressure monitoring.  The
 company trades on the Nasdaq small cap market under the symbol MDWV.
     Statements made in this release that are stated as expectations, plans,
 beliefs, anticipations, prospects or future estimates or which otherwise look
 forward in time are considered "forward-looking statements" and involve a
 variety of risks and uncertainties, known and unknown, which are likely to
 affect the actual results.  The following factors, among others, as well as
 factors discussed in the company's filings with the SEC, have affected and, in
 the future, could affect the company's actual results:  resistance to the
 acceptance of new products, the market acceptance of the Vasotrac(R) monitor,
 the Vasotrax(TM) Hand-held Monitor, and other products of the company,
 hospital budgeting cycles, the possibility of adverse or negative commentary
 from clinical researchers or other users or evaluators of the company's
 products, the company's success in creating effective distribution channels
 for its products, the company's ability to scale up its manufacturing process,
 and delays in product development or enhancement or regulatory approval.
 Consequently, no forward-looking statement can be guaranteed and actual
 results may vary materially.
 
 

SOURCE Medwave Inc.
    ST. PAUL, Minn., April 19 /PRNewswire/ -- Medwave, Inc. (Nasdaq: MDWV)
 announced today that Nihon Kohden, Tokyo Japan, will assist Medwave in
 submitting the Vasotrax(TM) Hand-held Blood Pressure Monitor to Japans
 Ministry of Health and Welfare.  Later in the year, the companies will review
 the possibility of Nihon Kohden representing Medwaves Vasotrax Hand-held Blood
 Pressure Monitor in the Japanese Market.
     Medwave just recently introduced the Vasotrax Hand-held Blood Pressure
 Monitor.  With Vasotrax, clinicians can obtain spot blood pressure readings in
 approximately 15 seconds.  The Vasotrax eliminates the need for a conventional
 blood pressure cuff, uses no mercury, and has been compared to an arterial
 catheter, with an accuracy of 0.90.  Conventional non-invasive blood pressure
 products typically have an accuracy correlation of 0.70-0.80, versus an
 A-line.  In the future users will be able to store over 200 readings, which
 can be download into a PC Based System, for up to 16 patients.
     Medwave and Nihon Kohden have two other existing agreements.  In Japan,
 Nihon Kohden is the exclusive distribution company for the Vasotrac(R) APM205A
 Continual Non-invasive Blood Pressure Monitor, which was submitted to Japans
 Ministry of Health and Welfare several months ago.  Also, in an agreement
 finalized in September 2000, Medwave supplies Nihon Kohden with an OEM module
 of the Vasotrac for the Nihon Kohden Product Family.
     The Vasotrac is designed for measuring a patient's blood pressure on a
 continual basis.  It provides updates approximately once every 15 heartbeats,
 with an accuracy correlation of 0.97 versus an arterial catheter.  The
 Vasotrac is being marketed in several major countries in the world including
 the United States and Europe.  The Vasotrac is currently being used in
 anesthesiology, critical care, emergency rooms, and cardiology departments.
 Users of the Vasotrac have reported a reduction in the need for arterial
 catheters, when used with specific patients.
     Medwave, Inc. headquartered in St. Paul, Minn., USA, develops and
 manufactures non-invasive blood pressure products.  Its Vasotrax Hand-held
 Monitor and the Vasotrac(R) APM205A monitor, the company's related monitoring
 system, are new approaches to non-invasive blood pressure monitoring.  The
 company trades on the Nasdaq small cap market under the symbol MDWV.
     Statements made in this release that are stated as expectations, plans,
 beliefs, anticipations, prospects or future estimates or which otherwise look
 forward in time are considered "forward-looking statements" and involve a
 variety of risks and uncertainties, known and unknown, which are likely to
 affect the actual results.  The following factors, among others, as well as
 factors discussed in the company's filings with the SEC, have affected and, in
 the future, could affect the company's actual results:  resistance to the
 acceptance of new products, the market acceptance of the Vasotrac(R) monitor,
 the Vasotrax(TM) Hand-held Monitor, and other products of the company,
 hospital budgeting cycles, the possibility of adverse or negative commentary
 from clinical researchers or other users or evaluators of the company's
 products, the company's success in creating effective distribution channels
 for its products, the company's ability to scale up its manufacturing process,
 and delays in product development or enhancement or regulatory approval.
 Consequently, no forward-looking statement can be guaranteed and actual
 results may vary materially.
 
 SOURCE  Medwave Inc.